

Development of an intelligent nano-object for the treatment of particularly resistant solid tumors, such as glioblastoma, pancreatic or prostate cancer : CDMO, technical, R&D partners and investors are sought

Summary

Profile type	Company's country	POD reference
Technology offer	France	TOFR20250613018
Profile status	Type of partnership	Targeted countries
PUBLISHED	Investment agreement Commercial agreement with technical assistance Research and development cooperation agreement	• World
Contact Person	Term of validity	Last update
Enrico FRANZIN	16 Jun 2025 16 Jun 2026	16 Jun 2025

General Information

Short summary

A French company is developing a disruptive treatment for particularly resistant tumors based on the first dual therapy nanotherapy amplifying efficacy and effect of radiotherapy and chemotherapy. The company is seeking different kind of partners in nanomedicine and pharmaceutical field to accelerate its development.

Full description

A French company is developing a breakthrough innovation in oncology with a patented nanomedicine incorporating a unique dual therapy: a chemotherapy molecule combined with gold nanoparticles.

This combination amplifies the effect of radiotherapy, optimizes the efficacy of chemotherapy and enables tumors to be targeted via intra-tumoral administration, thus limiting side effects for patients. This intelligent nano-object could revolutionize the treatment of particularly resistant solid tumors, such as glioblastoma, pancreatic or prostate cancer.

The company encapsulates gold nanoparticles and chemodrug in a nanocapsule that allows very high and efficient passage into glioblastoma cells. The initial POC in vivo results are very promising in terms of animal survival, the

median survival of animals treated with this nanomedicine is equal to that of animals without glioblastoma.

The company is seeking for its development 4 types of partners:

- Pharmaceutical laboratories developing innovative molecules or with molecules that could be optimised in the cargo ship,
- CDMO to manufacture the product in bigger quantities,
- Organisations to cooperate with and possibly in the framework of European projects
- Investors (business angels, family offices, Venture Capital)

Advantages and innovations

The world's only dual-therapy nanomedicine: radioenhancer and chemotherapy molecules

Promising results against aggressive cancer such as glioblastoma and possibility to address quickly other kind of cancers

Limitation of side-effects for patients

Technical specification or expertise sought

Stage of development

Available for demonstration

IPR Status

IPR granted

IPR Notes

Sustainable Development goals

- **Goal 3: Good Health and Well-being**
- **Goal 17: Partnerships to achieve the Goal**

Partner Sought

Expected role of the partner

Pharmaceutical companies or private laboratories developing innovative molecules for cancer treatment

CDMO to manufacture the product

For EU research and innovation projects : Any organisation with an interest in cancer eg: glioblastoma, pancreatic

cancer, prostate cancer, which presents in AI, innovative therapeutic access, safety analysis, co-encapsulation of innovative molecules in chemotherapy, which processes megadata concerning cancer, which proposes medical devices in line with the development made by the French company

Investors : Venture capital, business angels, family offices

Type of partnership

Investment agreement

Commercial agreement with technical assistance

Research and development cooperation agreement

Type and size of the partner

• **SME 11-49**

• **SME <=10**

• **Big company**

• **SME 50 - 249**

Dissemination

Technology keywords

- **06001003 - Cytology, Cancerology, Oncology**
- **06004 - Micro- and Nanotechnology related to Biological sciences**
- **06001014 - Neurology, Brain Research**

Targeted countries

- **World**

Market keywords

- **05003001 - Therapeutic services**
- **05003005 - Drug delivery and other equipment**
- **05005014 - Oncology**

Sector groups involved

- **Health**